1092977-61-1 Usage
General Description
Evenamide is a novel chemical compound that has been developed as an investigational antiepileptic drug. It acts as a voltage-gated sodium channel blocker and has shown potential in reducing seizures in patients with epilepsy. Evenamide works by stabilizing the neuronal membrane potential and inhibiting excessive neuronal firing, thereby preventing the spread of abnormal electrical activity in the brain. In preclinical studies, it has demonstrated good safety and tolerability profiles, and early clinical trials have also shown promising results in terms of efficacy and tolerability. Evenamide represents a potential new treatment option for individuals with epilepsy, particularly those who have not responded well to currently available antiepileptic medications. Further research and development are ongoing to fully understand its efficacy and safety in individuals with epilepsy.
Check Digit Verification of cas no
The CAS Registry Mumber 1092977-61-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,9,2,9,7 and 7 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1092977-61:
(9*1)+(8*0)+(7*9)+(6*2)+(5*9)+(4*7)+(3*7)+(2*6)+(1*1)=191
191 % 10 = 1
So 1092977-61-1 is a valid CAS Registry Number.
1092977-61-1Relevant articles and documents
PROCESS FOR THE PRODUCTION OF SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO]ALKANEAMIDE DERIVATIVES
-
, (2020/10/28)
The present invention refers to a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R is (C3-C10)alkyl, or ω-trifluoro(C3-C10)alkyl; R1 and R2 are, independently, hydrogen, hydroxy, (C1-C8) alkoxy, (C1-C8) alkylthio, halo, trifluoromethyl or 2,2,2-trifluoroethyl; or one of R1 and R2 is in ortho position to the R-O- group and, taken together with the same R-O-, represents a Formula (A) group where Ro is (C2-C9)alkyl; R3 and R4 are, independently, hydrogen, (C1-C4)alkyl; or R4 is hydrogen and R5 is a group selected from -CH2-OH, -CH2-O-(C1-C6)alkyl, -CH(CH3)-OH, -(CH2)2-S-CH3, benzyl and 4-hydroxybenzyl; or R4 and R5, taken together with the adjacent carbon atom, form a (C3-C6)cycloalkyl residue; R5 and R6 are independently hydrogen or (C1-C6)alkyl; or taken together with the adjacent nitrogen atom form a 5-6 membered monocyclic saturated heterocycle, optionally containing one additional heteroatom chosen among -O-, -S- and -NR7- where R7 is hydrogen or (C1-C6) alkyl; and wherein optionally one or more hydrogen atom in the groups R, R1, R2, R3, R4, R5 and R6, preferably in the R group, can be substituted by a deuterium atom.
